文献速递肾小球疾病

奥妥珠单抗与利妥昔单抗治疗原发性膜性肾病的比较

Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy.
PubMed 文献 · Clin J Am Soc Nephrol · 2024-08-29

本研究比较奥妥珠单抗与利妥昔单抗治疗原发性膜性肾病(MN)的有效性和安全性。12个月时奥妥珠单抗组达到主要结局(部分或完全缓解)的比例为95%,利妥昔单抗组为67%(OR 10.00,95%CI 1.21-82.35,P=0.03),且完全缓解率更高(38% vs 14%)。

要点

  • 奥妥珠单抗12个月临床缓解率显著高于利妥昔单抗(95% vs 67%)。
  • 奥妥珠单抗完全缓解率更高(38% vs 14%)。
  • 两组安全性相似,耐受性良好。

核心结论

  • 在原发性膜性肾病患者中,奥妥珠单抗治疗12个月临床缓解率高于利妥昔单抗,可能与6个月时更高的免疫学缓解有关,且安全性相似。

主要发现

  • 12个月时主要结局(部分或完全缓解)在奥妥珠单抗组为95%(20/21),利妥昔单抗组为67%(28/42),OR 10.00(95%CI 1.21-82.35),P=0.03。
  • 完全缓解率奥妥珠单抗组为38%,利妥昔单抗组为14%,OR 3.69(95%CI 1.08-12.68),P=0.04。
  • 在PLA2R相关原发性MN亚组中,奥妥珠单抗组CD19 B细胞计数中位数0(0-6)cells/μl,利妥昔单抗组20(3-58)cells/μl,P=0.002。
  • 6个月时免疫学缓解(PLA2R抗体<2 RU/ml)率奥妥珠单抗组为92%(12/13),利妥昔单抗组为64%(16/25),P=0.06。
  • 两种治疗方案均耐受良好。

关键数值与推荐

  • 纳入标准:原发性MN,尿蛋白≥3.5 g/24h,eGFR≥30 ml/min per 1.73 m2,且已使用ACEI/ARB治疗6个月。
  • 主要结局:12个月时部分或完全缓解的复合终点。
  • 免疫学缓解定义:PLA2R抗体<2 RU/ml。

临床怎么用

  • 对于原发性膜性肾病患者,奥妥珠单抗可能提供更高的12个月临床缓解率和完全缓解率,且安全性相似,可考虑作为利妥昔单抗的替代选择。

局限性

  • 为回顾性研究,可能存在选择偏倚和混杂因素。
  • 亚组分析中免疫学缓解的P值为0.06,未达到统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Obinutuzumab induced more remission than rituximab at 12 months in patients with primary membranous nephropathy. Obinutuzumab shared a similar safety profile as rituximab in patients with primary membranous nephropathy. BACKGROUND: This study compared the effectiveness and safety profiles of obinutuzumab and rituximab in the treatment of patients with primary membranous nephropathy (MN). METHODS: Patients with primary MN who had urine protein ≥3.5 g/24 hours and eGFR ≥30 ml/min per 1.73 m2 despite 6 months of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker and treatment with obinutuzumab or rituximab were included and matched by propensity score (ratio: 1:2) on the basis of age, sex, urine protein, eGFR, and titers of Anti-Phospholipase A2 receptor (PLA2R) antibody. The primary outcome was defined as a combination of partial or complete remission at 12 months. Logistic regression models, Kaplan–Meier curves, and absolute risk differences were used to compare the therapeutic effectiveness and safety profiles of obinutuzumab and rituximab. RESULTS: Sixty-three patients with primary MN were included in the study, with 21 patients receiving obinutuzumab and 42 patients receiving rituximab. At 12 months, the primary outcome was achieved in 20 of 21 patients in the obinutuzumab group and 28 of 42 patients in the rituximab group (obinutuzumab versus rituximab: 95% versus 67%; odds ratio, 10.00; 95% confidence intervals, 1.21 to 82.35; P = 0.03). Moreover, patients in the obinutuzumab group acquired more complete remission (obinutuzumab versus rituximab: 38% versus 14%; odds ratio, 3.69; 95% confidence interval, 1.08 to 12.68; P = 0.04). In PLA2R-associated primary MN subgroup analyses, patients in the obinutuzumab group sustained lower CD19 B-cell counts (CD19 B-cell counts: median [interquartile range] 0 [0–6] cells/μl versus 20 [3–58] cells/μl, P = 0.002) and were more prone to achieve immunological remission (defined as PLA2R antibody <2 RU/ml) at 6 months (obinutuzumab versus rituximab: 92% [12 out of 13] versus 64% [16 out of 25], P = 0.06) than rituximab. Both treatment regimens were well tolerated. CONCLUSIONS: Our study demonstrated that obinutuzumab is associated with higher odds of clinical remission compared with rituximab at 12 months, which may be due to higher immunological remission at 6 months with a similar safety profile in patients with primary MN.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hu X, Zhang M, Xu J, et al. Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2024. PMID: 39207845. doi:10.2215/CJN.0000000000000555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。